IDH1 and acute myeloid leukemia: Consequently, IDH1 (ivosidenib) and IDH2 (enasidenib) inhibitors have been approved by the US Food and Drug Administration (FDA) for targeted therapy of AML, and ivosidenib has recently been approved for locally advanced or metastatic cholangiocarcinoma.18, 19, 20